This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Myotonia congenita (Thomsen disease / Becker type)Myotonia Congenita (Thomsen / Becker Type)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: G71.1 | Special Copayment Reduction: V012 | Registration validity period: 5 years
B. SynonymsMyotonia congenita NOS, recessive [Becker] myotonia congenita, dominant [Thomsen] myotonia congenita, Myotonia Congenita, Thomsen disease, Becker myotonia
C. Adult onsetLikelihood of first onset in adulthood: low — The Thomsen type first presents in infancy to childhood and the Becker type in childhood to adolescence, but some cases go unrecognized until adulthood.
1. HistoryGo to section
2. CausesGo to section
3. GeneticsGo to section
4. General epidemiologyGo to section
5. PathophysiologyGo to section
6. SymptomsGo to section
7. SignsGo to section
8. ScreeningGo to section
9. DiagnosisGo to section
10. TreatmentGo to section
11. PrognosisGo to section
12. PreventionGo to section
13. ReferencesGo to section

1. History

Myotonia congenita became known to medicine in 1876 when the Danish physician Julius Thomsen first described in detail the muscle stiffness affecting himself and four generations of his family. Thomsen himself had the disease, and by introducing the term 'myotonia congenita' he first named it as a hereditary disease characterized by delayed muscle relaxation after voluntary movement. From the late 19th to the early 20th century, neurologists refined the clinical description. In 1971, the German Peter Emil Becker described a more severe form of myotonia not previously reported, characterized by a recessive pattern of inheritance and accompanied by transient weakness and muscle hypertrophy. This came to be called the Becker type, or recessive myotonia congenita. The molecular genetic basis was revealed in 1992 by Koch et al., who established that mutations of the CLCN1 gene (chloride channel gene) cause both forms. Since then, more than 300 pathogenic CLCN1 variants have been reported, confirming that variants of the same gene can produce dominant or recessive phenotypes.

2. Causes

Myotonia congenita is caused by pathogenic variants of the CLCN1 gene (7q34), which encodes the main chloride channel of skeletal muscle. The ClC-1 chloride channel plays a key role in normal repolarization of the muscle cell membrane, and loss of function of this channel causes hyperexcitability of the muscle cell membrane, producing myotonia, in which relaxation after voluntary contraction is delayed.

More than 300 pathogenic CLCN1 variants have been reported to date, including various variant types such as missense, nonsense, splicing, and small insertions/deletions. Some variants have been reported in both the dominant and recessive forms, making the genotype-phenotype correlation complex.

3. Genetics

Myotonia congenita is caused by pathogenic variants of the CLCN1 gene (7q34). Depending on the nature of the variant, the mode of inheritance is either autosomal dominant (Thomsen type) or autosomal recessive (Becker type).

CharacteristicsThomsen type (dominant)Becker type (recessive)
Mode of inheritanceAutosomal dominantAutosomal recessive
Age of onsetInfancy to childhoodChildhood to adolescence
Clinical severityMild to moderateModerate to severe
WeaknessRareTransient weakness characteristic
Muscle hypertrophyMildMarked muscle hypertrophy possible
PrevalenceAbout 1/400,000About 1/25,000

Some CLCN1 variants have incomplete penetrance, so phenotypic diversity is observed even within the same family. In particular, some dominant-form variants show sex differences in penetrance, sometimes with higher penetrance in males. Genetic testing helps predict the mode of inheritance based on variant location and type, but it is difficult to fully predict the clinical outcome of individual variants.

4. General epidemiology

Myotonia congenita is a rare genetic disease, with a worldwide prevalence of both forms combined estimated at about 1/100,000. The Becker type (recessive) is more prevalent than the Thomsen type (dominant), reported at about 1/25,000–1/50,000. The prevalence of the Thomsen type is about 1/400,000. Prevalence is known to be higher in Scandinavian countries (especially Denmark and Finland) than in other regions, which may be related to a founder effect. Prevalence by sex is similar in men and women for both forms, but with some variants of the dominant form, men tend to show a more severe phenotype. Domestic incidence data are limited, but the Becker type is diagnosed more frequently in clinical practice.

5. Pathophysiology

ClC-1 (the CLCN1 gene product) is the main chloride channel, responsible for about 75–80% of the resting conductance of the skeletal muscle cell membrane. Normally, after a muscle action potential, ClC-1 channels open and chloride ions flow into the cell, stabilizing (repolarizing) the membrane potential.

When ClC-1 channel conductance decreases due to CLCN1 loss-of-function variants, the muscle cell membrane is placed in a hyperexcitable state. As a result, repetitive action potentials occur continuously even after a single voluntary contraction stimulus (sustained depolarization), resulting in myotonia, in which the muscle cannot relax. The transient weakness observed in the Becker type is understood to be related to cumulative inactivation of sodium channels due to repetitive action potentials.

The warm-up phenomenon (easing of myotonia with repeated exercise) is explained by a mechanism in which extracellular potassium ion concentration rises as muscle activity is repeated, contributing to ClC-1 channel activation and membrane potential stabilization.

6. Symptoms

The core symptom of myotonia congenita is myotonia, an abnormal delay in relaxation after voluntary muscle contraction. Skeletal muscles throughout the body are involved, especially prominently the muscles of the lower limbs, upper limbs, face, and tongue.

Myotonic symptoms

Symptoms specific to the Becker type

Impact on quality of life

7. Signs

Myotonia-related signs

Muscle hypertrophy and body habitus

Laboratory findings

Other

8. Screening

9. Diagnosis

The disease is suspected from clinical symptoms and EMG findings and confirmed by molecular genetic testing of the CLCN1 gene.

Molecular genetic testing

Ancillary diagnosis

Differential diagnosis

10. Treatment

Myotonia congenita is not life-threatening, and the goals of treatment are relief of myotonic symptoms and improvement in quality of life.

Drug therapy

Non-pharmacological treatment

Anesthetic management

11. Prognosis

Myotonia congenita is a non-progressive disease without life-threatening complications and is not accompanied by serious visceral involvement or cognitive impairment. Most patients have a normal life span, and symptoms can be adequately controlled with appropriate treatment. The myotonia itself may improve somewhat with age but rarely disappears completely. The Becker type has more severe symptoms than the Thomsen type, with a risk of accidents such as falls due to transient weakness, but it does not progress to long-term weakness or muscle atrophy. Persistent mild weakness in adulthood has also been reported in some patients with the Becker type. Symptoms may change during pregnancy, and transient myotonic symptoms may appear in newborns.

12. Prevention

13. References

  1. Koch MC, Steinmeyer K, Lorenz C, et al. The skeletal muscle chloride channel in dominant and recessive human myotonia. Science. 1992;257(5071):797–800. PMID: 1379744
  2. Statland JM, Fontaine B, Hanna MG, et al. Review of the diagnosis and treatment of periodic paralysis. Muscle Nerve. 2018;57(4):522–530. PMID: 28846808
  3. Trip J, Drost G, van Engelen BG, Faber CG. Drug treatment for myotonia. Cochrane Database Syst Rev. 2006;(1):CD004762. PMID: 16437491
  4. Stunnenberg BC, Raaphorst J, Groenewoud HM, et al. Effect of mexiletine on muscle stiffness in patients with nondystrophic myotonia evaluated using aggregated N-of-1 trials. JAMA. 2018;320(22):2344–2353. PMID: 30535218
  5. Colding-Jorgensen E. Phenotypic variability in myotonia congenita. Muscle Nerve. 2005;32(1):19–34. PMID: 15880415
  6. Fialho D, Bhatt DL, Hanna MG, et al. Non-dystrophic myotonias: a consensus guide to diagnosis and management. Pract Neurol. 2018;18(6):484–498. PMID: 29959219
  7. Suetterlin K, Männikkö R, Hanna MG. Complex phenotype in patients with CLCN1 mutations. Neurology. 2017;88(14):1310–1317. PMID: 28275018
  8. Orhan Sencer G, Bulut NI, Durmus H, et al. Clinical and genetic analysis and literature review of children with myotonia congenita due to CLCN1 mutations. Eur J Paediatr Neurol. 2025. PMC12150482
  9. Kuntzer T, Flocard F, Vial C, et al. Exercise test in muscle channelopathies and other muscle disorders. Muscle Nerve. 2000;23(7):1089–1094. PMID: 10882998
  10. Moxley RT 3rd, Logigian EL, Martens WB, et al. Computerized hand grip myometry reliably measures myotonia and muscle strength in myotonia congenita. Muscle Nerve. 2007;36(3):320–328. PMID: 17566114